Trade this ETF at your broker
Index | NYSE Arca Biotechnology |
Investment focus | Equity, United States, Health Care |
Fund size | EUR 6 m |
Total expense ratio | 0.60% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 18.02% |
Inception/ Listing Date | 27 May 2020 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | First Trust |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | First Trust Advisors L.P. |
Custodian Bank | The Bank of New York Mellon SA/NV, Dublin Branch |
Revision Company | Deloitte |
Fiscal Year End | 31 December |
Swiss representative | Waystone Fund Services (Switzeland) SA |
Swiss paying agent | Banque Cantonale de Genève |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | No ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | |
Securities lending | No |
Securities lending counterparty |
Natera | 4.77% |
Bruker | 4.08% |
Halozyme Therapeutics | 3.89% |
Repligen Corp | 3.76% |
Waters | 3.68% |
Mettler-Toledo Intl | 3.54% |
Alkermes | 3.54% |
Intra-Cellular Therapies | 3.52% |
PTC Therapeutics | 3.47% |
Regeneron Pharmaceuticals | 3.47% |
United States | 86.77% |
Ireland | 3.54% |
Other | 9.69% |
Health Care | 90.31% |
Other | 9.69% |
YTD | -6.82% |
1 month | -5.96% |
3 months | -4.52% |
6 months | +1.63% |
1 year | -7.40% |
3 years | -2.28% |
5 years | - |
Since inception (MAX) | -10.51% |
2023 | -1.30% |
2022 | +1.20% |
2021 | +4.30% |
2020 | - |
Volatility 1 year | 18.02% |
Volatility 3 years | 22.28% |
Volatility 5 years | - |
Return per risk 1 year | -0.41 |
Return per risk 3 years | -0.03 |
Return per risk 5 years | - |
Maximum drawdown 1 year | -15.50% |
Maximum drawdown 3 years | -20.99% |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -25.05% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
Borsa Italiana | EUR | FBT | FBT IM FBTINAV | FBT.MI | |
London Stock Exchange | GBX | FBT | FBT LN FBTINAV | ||
London Stock Exchange | GBP | - | FBT LN | ||
London Stock Exchange | USD | FBTU | FBTU LN FBTINAV |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Nasdaq US Biotechnology UCITS ETF | 410 | 0.35% p.a. | Accumulating | Sampling |
Invesco Nasdaq Biotech UCITS ETF | 390 | 0.40% p.a. | Accumulating | Swap-based |
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 34 | 0.35% p.a. | Distributing | Sampling |